Neuroscientists have made a major advance in modeling the human brain in mice, offering a new way to study conditions like cerebral palsy. Ethicists ask if it changes how these mice should be treated.

Parkinson's disease appears to disrupt a brain network involved in everything from movement to memory.

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal stimulation.

Older Black Americans are about twice as likely to develop Alzheimer’s or other dementias as older white Americans, according to the Alzheimer’s Association. Yet, awareness and resources to address these diseases within the Black community have often lagged behind. That’s where Alter Dementia steps in.

When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily pulling it off the market.

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.